GSK (GSK) Share Price, News & Analysis

Company Overview

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Key Stats

• Today's Range: 1,803 to 1,856
• 50-Day Range: 1,848 to 2,029
• 52-Week Range: 1,288.61 to 2,282
• Volume: 14.90 million shs
• Average Volume: 8.50 million shs
• Market Capitalization: £74.02 billion
• P/E Ratio: 15.69
• Dividend Yield: 3.59%
• Price Target: GBX 2,048.57
• Consensus Rating: Hold

GSK Stock Analysis - MarketRank™

GSK scored higher than 68% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Hold

Consensus Rating

GSK has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on no strong buy ratings, 2 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

GSK has a consensus price target of GBX 2,048.57, representing about 10.9% upside from its current price of GBX 1,848.

Amount of Analyst Coverage

GSK has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of GSK is 15.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.84.

Price to Earnings Ratio vs. Sector

The P/E ratio of GSK is 15.69, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 268.81.

Price to Earnings Growth Ratio

GSK has a PEG Ratio of 1.24. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

GSK has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GSK.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

GSK is a leading dividend payer. It pays a dividend yield of 3.59%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

GSK does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of GSK is 56.88%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.19

News Sentiment

GSK has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for GSK this week, compared to 6 articles on an average week.

Search Interest

45 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 114% compared to the previous 30 days.

MarketBeat Follows

2 people have added GSK to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.8 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of GSK in the last three months. Multiple insiders buying is a strong bullish signal.

Insider Buying vs. Insider Selling

In the past three months, GSK insiders have bought more of their company's stock than they have sold. Specifically, they have bought £134,819.42 in company stock and sold GBX 0 in company stock.

Percentage Held by Insiders

0.20% of the stock of GSK is held by insiders.

Percentage Held by Institutions

56.95% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/28/2026
• Today: 8/15/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: LON:GSK
• CIK: N/A
• Web: www.gsk.com
• Phone: +44-20-80475000
• Fax: N/A
• Employees: 70,212
• Year Founded: N/A

Price Target and Rating

• Average Price Target for GSK: GBX 2,048.57
• High Price Target: GBX 2,500
• Low Price Target: GBX 1,500
• Potential Upside/Downside: +10.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 117.80
• Trailing P/E Ratio: 15.69
• Forward P/E Ratio: 10.50
• P/E Growth: 1.24
• Net Income: £2.50 billion
• Net Margins: 14.52%
• Pretax Margin: N/A
• Return on Equity: 28.35%
• Return on Assets: 9.56%

Debt

• Debt-to-Equity Ratio: 103.36
• Current Ratio: 0.82
• Quick Ratio: 0.73

Sales & Book Value

• Annual Sales: £33.20 billion
• Price / Sales: 2.23
• Cash Flow: GBX 226.88 per share
• Price / Cash Flow: 8.15
• Book Value: GBX 329.73 per share
• Price / Book: 5.60

Miscellaneous

• Outstanding Shares: 4,005,611,000
• Free Float: N/A
• Market Cap: £74.02 billion
• Optionable: Not Optionable
• Beta: 0.30